We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic "Hotspots” Tailor Therapies for Bowel Cancer Treatment

By LabMedica International staff writers
Posted on 22 Feb 2010
A new study has identified the repetition frequency of new genetic "hotspots,” which could help doctors offer personalized therapies for bowel cancer patients.

Researchers at the University of Dundee (United Kingdom) carried out a genetic analysis on 106 bowel cancer tumor samples to search for the frequency of known faults in a key gene called K-Ras--an important protein which acts as an "on-off switch” in cells to control growth--since it is already known that in some bowel cancers the K-Ras gene is faulty, leaving the switch permanently "on.” The researchers screened the colorectal tumors for additional K-Ras mutation phenotypes and Ras guanine triphosphate (GTP)-ase activating assays and gene and pathway changes induced by individual K-Ras mutants. More...


The researchers found that besides the current K-Ras "hotspots” in codons 12, 13, and 61, four additional K-Ras mutations (Leu19Phe, Lys117Asn, Ala146Thr, and Arg164Gln) were identified, most commonly at codon 146. The researchers additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumors. According to the researchers, the study suggests that as many as 33% of bowel cancer patients have a K-Ras fault. As a result, they recommend future mutation screening to facilitate optimal patient selection for treatment with Epidermal Growth Factor Receptor (EGFR)-targeted therapies should therefore be extended to codon 146, and in addition should consider the unique molecular signatures associated with individual K-Ras mutations. The study was published early online on February 9, 2010, in the British Journal of Cancer.

"These results highlight additional gene faults which potentially could be tested for in bowel cancer patients to determine which people will respond best to which drugs,” said lead author Gillian Smith, Ph.D. "The next stage is to develop effective tests to screen for these mutation 'hotspots' to help doctors to plan the most effective treatment strategies for bowel cancer patients - and this will encourage scientists to also focus their efforts on finding new treatments for patients with faulty K-Ras genes to give them more options.”

Targeted therapies are drugs that are designed to treat cancer cells while minimizing damage to normal, healthy cells. The drugs interfere with specific pathways involved in cancer cell growth or survival, such as blocking growth signals and reducing the blood supply to cancer cells; others stimulate the immune system to recognize and attack the cancer cell. The two types of targeted therapy that are currently being used for colorectal cancer are EGFR inhibitors--such as panitumumab, a monoclonal antibody that binds to and blocks EGFR--and antiangiogenic drugs.

Related Links:

University of Dundee



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.